Mateon Therapeutics Inc (OTCMKTS:MATN)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.16 and traded as high as $0.26. Mateon Therapeutics shares last traded at $0.26, with a volume of 17,966 shares changing hands.
A number of equities research analysts have recently issued reports on MATN shares. HC Wainwright reiterated a “hold” rating on shares of Mateon Therapeutics in a research report on Monday, April 22nd. ValuEngine upgraded shares of Mateon Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of Mateon Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th.
The stock’s 50 day moving average price is $0.20 and its two-hundred day moving average price is $0.16.
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.